IOL CHEMICALS & PHARMACEUTICALS LTD. Q2 FY26 Results
IOLCPQ2 FY26 ResultsAnnounced 11 Nov 2025, 03:31 pm| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 567.53 | 2.9% | 8.0% |
| Total Income | 574.41 | 2.8% | 7.9% |
| Expenditure | 533.92 | 4.0% | 5.5% |
| PBT | 40.49 | 11.0% | 56.1% |
| Net Profit | 29.97 | 11.7% | 56.5% |
| OPM | 10.06% | 1.20pp | 10.55pp |
| NPM | 5.22% | 0.85pp | 1.62pp |
| EPS | 1.02 | 12.1% | 68.7% |
IOL Chemicals & Pharmaceuticals Reports Q2 & H1 FY26 Results: 56.7% PAT Growth, Strategic Progress in Pharmaceuticals and Chemicals Business
11 Nov 2025 · 11 Nov 2025, 06:12 pm
Summary
IOL Chemicals & Pharmaceuticals Ltd., one of the leading manufacturers of Bulk Drugs & Specialty Chemicals, announced its Financial Results for the quarter and half year ended 30 September 2025. The company reported a 7.9% Y-o-Y increase in Revenue from Operations, a 33.3% Y-o-Y increase in EBITDA, and a 56.7% Y-o-Y increase in Profit After Tax.
Key Highlights
- 1
Revenue from Operations for Q2 FY26 was 567.5 Cr, a 7.9% Y-o-Y increase.
- 2
EBITDA for Q2 FY26 was 64.0 Cr, a 33.3% Y-o-Y increase.
- 3
Profit After Tax for Q2 FY26 was 30.0 Cr, a 56.7% Y-o-Y increase.
- 4
Received EDQM’s Certificate of Suitability for Pantoprazole Sodium Sesquihydrate Process-lll on 14th October 2025.
- 5
Incorporated IOL Pharmaxis UK Limited in October 2025 to strengthen international operations.
Management Comments
Mr Vikas Gupta
Joint Managing Director
Q2 FY26 reflects IOL’s continued operational strength and strategic focus, with revenue from operations rising 7.9% and EBITDA improving 33.3% year-on-year. Importantly, EBITDA margin improved to 11.1% from 9.1%, driven by better operating leverage and cost efficiencies. Profit After Tax increased 56.7% year-on-year with PAT margin expanding to 5.2% from 3.6%, underscoring the strength of our integrated model. However, PAT was marginally impacted ona sequential basis due to higher fuel costs, following the Punjab floods, which temporarily disrupted supply chains and elevated energy inputs. Both our Pharmaceuticals and Chemicals segments reported YoY EBIT growth, reflecting improved operating discipline and recovery in volumes. The Pharmaceuticals segment continues to gain momentum, led by strong traction in non-Ibuprofen APIs. We also incorporated IOL Pharmaxis UK Limited, a strategic step to strengthen our international operations and improve customer proximity in key regions. In the Chemicals segment, we are witnessing steady volume recovery, even as pricing remains under pressure. Going ahead, our focus remains on cost optimisation, process discipline, and maintaining a balanced product mix across end-use sectors.
Informational and educational content only. Not investment advice.